PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Immunol. Author manuscript; available in PMC 2013 July 1.
Published in final edited form as:
PMCID: PMC3381926
NIHMSID: NIHMS375564

Relative contributions of Dectin-1 and complement to immune responses to particulate β-glucans1

Abstract

Glucan particles (GPs) are Saccharomyces cerevisiae cell walls chemically extracted so they are composed primarily of particulate β1,3-D-glucans. GPs are recognized by Dectin-1 and are potent complement activators. Mice immunized with antigen-loaded GPs develop robust Ab and CD4+ T cell responses. Here, we examined the relative contributions of Dectin-1 and complement to GP phagocytosis and antigen-specific responses to immunization with OVA encapsulated in GPs (GP-OVA). The in vitro phagocytosis of GPs by BMDCs was facilitated by heat-labile serum component(s) independently of Dectin-1. This enhanced uptake was not seen with serum from complement component 3 (C3) knockout (C3−/−) mice and was also inhibited by blocking Abs directed against complement receptor 3 (CR3). Following i.p. injection, percent phagocytosis of GPs by peritoneal macrophages was comparable in wild-type and Dectin-1−/− mice and was not inhibited by the soluble β-glucan antagonist, laminarin. In contrast, a much lower percentage of peritoneal macrophages from C3−/− mice phagocytosed GPs and this percentage was further reduced in the presence of laminarin. Subcutaneous immunization of wild-type, Dectin-1−/− and C3−/− mice with GP-OVA resulted in similar antigen-specific IgG1 and IgG2c type Ab and CD4+ T cell lymphoproliferative responses. Moreover, while CD4+ Th1 and Th2 responses measured by ELISPOT were similar in the three mouse strains, Th17 responses were reduced in C3−/− mice. Thus, while Dectin-1 is necessary for optimal phagocytosis of GPs in the absence of complement, complement dominates when both an intact complement system and Dectin-1 are present. In addition, Th-skewing following GP-based immunization was altered in C3−/− mice.

Introduction

β-1,3-D-glucans are homopolymers of glucose which form the structural scaffold of the cell wall of medically important fungi (1). Considering the ubiquitous presence of this fungal pathogen-associated molecular pattern (PAMP), it is not surprising that host defenses have evolved to recognize and respond to β-1,3-D-glucans (2). Dectin-1, a C-type lectin highly expressed on phagocytes, including DCs, macrophages and neutrophils, serves as a pattern recognition receptor for β-1,3-D-glucans (3). Upon ligation of β-glucans to Dectin-1, a number of cellular events follow, such as phagocytosis, activation of signaling pathways and transcription factors, generation of reactive oxygen species, and release of cytokines/chemokines (4). The contribution of Dectin-1 to host defenses against fungal infections in vivo has been studied by comparing the susceptibility of wild-type and Dectin-1 knockout mice to fungal challenge. In some, but not all models of mycoses, mice with Dectin-1 deficiency manifested increased mortality. For example, Dectin-1 was shown to be required for optimal control of systemic Candida albicans infection in one study but dispensable in another study (5, 6). In humans, genetic variations in Dectin-1 and its downstream signaling pathways affect susceptibility to mucosal candidiasis but not candidemia (7, 8).

Particulate β-1,3-D-glucans directly activate the alternative pathway of complement (911). iC3b deposited on β-glucans is recognized by complement receptor 3 (CR3, CD11b/CD18) (12). CR3 also has a distinct β-glucan binding site (13). Although complement does not lyse fungi directly, most likely because of the rigid structure of the fungal cell wall, complement plays a unique role in host defenses against opportunistic fungal infections by promoting opsonophagocytosis and by the generation of the potent chemoattractants, C3a and C5a (14). Complement has been suggested to play an important role in the immune responses to β-glucans based on studies using β-1 glucans as an enhancement reagent for mAb-based anti-tumor treatment (1517).

We have demonstrated that S. cerevisiae-derived glucan particles (GPs) can be exploited to function as a vaccine adjuvant-delivery platform that elicits strong humoral and Th1- and Th17-biased CD4+ cellular responses to antigens entrapped in the particles (18). GPs are largely composed of β-1,6 branched, β-1,3-D-glucans, with ~2% chitin and less than 1% proteins (19). GPs are recognized by dectin-1 but are also potent complement activators (10, 18). Thus, in addition to serving as a promising vaccine platform, the size and biochemical properties of GPs make them excellent tools to dissect the role of β-1,3-D-glucans in the immune response to fungi. Here, we utilized Dectin-1−/− and C3−/− mice to study the relative contributions of Dectin-1 and complement to the uptake of GPs by mononuclear phagocytes and to immune outcomes following immunization with antigen-loaded GPs.

Materials and Methods

Chemicals and cell culture media

Chemical reagents were obtained from Sigma-Aldrich (St. Louis, MO), unless otherwise noted. RPMI 1640 media were purchased from Invitrogen Life Technologies (Carlsbad, CA). R10 medium is defined as RPMI 1640 containing 10% FBS (Tissue Culture Biologicals, Tulare, CA), 100 U/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine (Invitrogen) and 55 μM 2-ME (Invitrogen). Chicken OVA was purchased from Worthington Biochemical Corporation (Lakewood, NJ). Cells were incubated at 37°C in humidified air supplemented with 5% CO2.

Mice

Wild-type C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Dectin-1−/− mice were a gift from Gordon D. Brown (University of Aberdeen, United Kingdom). C3−/− mice (The Jackson Laboratory) were bred at the animal facility at the University of Massachusetts Medical School. Both strains of knockout mice were backcrossed at least 12 generations to the C57BL/6 background. Mice were specific-pathogen free and all animal procedures were conducted under a protocol approved by The University of Massachusetts Medical School Institutional Use and Care of Animals Committee.

GPs

GPs were prepared from S. cerevisiae (Fleischmann's Baker's yeast) by a series of alkaline and acidic extraction steps as previously described (2022). Briefly, the washed yeast cells were suspended in 1 M NaOH and heated at 90°C for 1h following centrifugation. Hot alkali extraction was then repeated. The particles were then suspended in water at pH 4.5 and heated at 75°C for 1 h, followed by successive washes of the particles with water (3×), isopropanol (4×) and acetone (2×). GPs were labeled with dichlorotriazinylaminofluorescein (DTAF) as previously described (21). Briefly, GPs (5 mg/ml) were incubated with DTAF (0.25 mg/ml) in 0.1 M borate buffer (pH 10.8) overnight at 37°C in the dark. Unreacted DTAF was then quenched by incubation with 1 M Tris (pH 8.3) for 30 min. GPs were extensively washed in sterile water, incubated overnight in 70% ethanol, washed three times with sterile PBS and counted.

Mouse BMDCs

BMDCs were generated as previously described with a slight modification (23, 24). Briefly, bone marrow cells obtained from the tibiae and femurs of 8- to 12-week-old mice were cultured in R10 medium supplemented with 10% GM-CSF conditioned medium from the mouse GM-CSF-secreting J558L cell line. Cells were fed with fresh GM-CSF-supplemented R10 on days 3 and 6. On day 8, nonadherent cells were collected and purified with the Magnetic Cell Separation System (MACS) using CD11c+ magnetic beads (Miltenyi Biotec, Auburn, CA) according to manufacturer's protocol. Where indicated, BMDCs were rendered unable to proliferate by incubation in RPMI 1640 containing 50 μg/ml mitomycin C for 30 min at 37°C followed by 3 washes with R10.

GP opsonization

Mouse blood was collected by cardiac puncture and immediately transferred to a micro-centrifuge tube on ice. After incubation on ice for 1 h, the blood was centrifuged at 4°C. The serum fraction was collected and divided into two aliquots. One aliquot was kept on ice while the other was heat-inactivated at 56°C for 30 min and then cooled on ice. GPs (up to 107 per 100 μl serum) were added to each tube of serum and incubated at room temperature for an additional 30 min. After centrifugation, the supernatant were removed and the GP-containing pellet was resuspended in R10.

Phagocytosis of fluorescent GPs by BMDCs

BMDCs in 400 μl medium (105/well) were incubated for 1 h at 37°C in 48-well cell culture treated plates with or without laminarin (1 mg/ml). In some experiments, anti-CR3 mAbs (M1/70 and 5C6) (25) or isotype control mAbs (rat IgG2b (Ebioscience, San Diego, CA) were also added at this time. mAbs were used at a final concentration of 10 μg/ml, as preliminary experiments demonstrated that this concentration of the anti-CR3 mAb gave maximal inhibition (data not shown). After incubation, DTAF-labeled GPs (F-GPs; 3×105/well, with or without mouse serum opsonization) were added into each well. After an additional 1 h incubation at 37°C, the wells were washed three times with Dulbecco's PBS (Lonza, Allendale, NJ) to remove free F-GPs and then examined under bright field and epifluorescence microscopy to determine the percentage of the cells with one or more F-GP particles in them.

Phagocytosis of F-GPs by peritoneal monocyte/macrophages

F-GPs (107) in 100 μl saline alone, or plus either 100 μl dextran (100 mg/ml, M.W. 10,000) or laminarin (1 mg/ml) were injected into the peritoneum of wild-type, Dectin-1−/− or C3−/− mice. After 1 h, 10 ml of cold PBS were injected into the peritoneum and collected back. Peritoneal cells were stained with the monocyte/macrophage marker, F4/80 (Ebioscience), and analyzed by FACS to measure the percentage of F-GP+ cells among F4/80+ cells.

GP-OVA

GPs containing complexed OVA (GP-OVA) were made as previously described with slight modification (18, 22). Briefly, 10 mg of dry GPs were swollen with 50 μl of OVA dissolved in water for 2 hs at 4°C to minimally hydrate the GPs allowing OVA diffusion into the hollow GP cavity. The samples were then frozen at −80°C and lyophilized. To hydraulically push the OVA inside the GPs the dry GP-OVA was again minimally hydrated with water for 2 hs at 4°C, frozen at −80°C and lyophilized. To trap the OVA inside the GPs, the dry GP-OVA formulations were heated to 50°C and swollen with 50 μl of 25 mg/mL tRNA (Sigma, St. Louis, MO derived from Torula yeast, type VI) in 0.15 M NaCl for 30 min. Then 500 μl of 5 mg/mL tRNA were added for 1 h at 50°C to complete the complexation reaction trapping the OVA inside the GPs. The GP-OVA particles were washed three times in 0.9% saline, resuspended in 70% ethanol for 30 min, washed three additional times in sterile 0.9% saline, counted and resuspended at 5 × 108 particles/mL in 0.9% saline. Aliquots were stored at −20°C until use. The typical loading efficiency was calculated to be greater than 95% by subtracting the unencapsulated OVA in the supernatant from the initial input using a fluorescent-labeled OVA tracer.

Immunization

For immunizations, wild-type, Dectin-1−/− and C3−/− mice (8–10 weeks old, 4 mice per group) received GP-OVA (5 × 107 GPs containing 3.3 μg OVA in 100 μl by s.c. injection over the abdomen. Mice were immunized 3 times at 2 week intervals and euthanized 2 weeks after last immunization. Blood, spleen and lymph nodes were then harvested for the Ab and T cell assays described below.

OVA-specific Ab ELISA

ELISA were performed as previously described with slight modification (18). Briefly, sera from immunized mice were diluted 1:40 and then progressively diluted twofold. Round-bottom 96-well plates coated with OVA were incubated with 50 μl diluted mouse sera at room temperature for 2 h. Wells were then washed and incubated with either biotin-conjugated rat anti-mouse IgG1 (BD Biosciences, San Jose, CA) or biotin-conjugated rat anti-mouse IgG2c (Jackson Immunoresearch, West Grove, PA) at room temperature for 1 h. Following 5 washes, the plates were incubated for 1 h with streptavidin-conjugated HRP (Ebioscience), washed 5 more times and then developed with tetramethylbenzidine solution (Ebioscience). OD450 was measured on a plate reader (Molecular Devices, Sunnyvale, CA). The Ab titer was defined as the dilution factor that was two-fold greater than the inflection point. Each dilution of serum was tested in duplicate.

T cell proliferation and ELISPOT assays

The assays were performed as previously described (18). Briefly, CD4+ T cells were purified from combined lymph node cells and splenocytes using negative selection CD4+ T cell isolation kits (Miltenyi Biotec, Auburn, CA) according to the manufacturer's protocol. To measure T cell proliferation, purified CD4+ T cells (105/well) were incubated in triplicate or quadruplicate for 4 days with mitomycin C-treated BMDCs (104/well) and the indicated stimuli in round-bottom wells of 96-well plates containing 200 μl R10. Cells were pulsed with [3H]-thymidine (1 μCi/well, Perkin Elmer, Boston, MA) for 24 h prior to harvest. Lymphoproliferation was then determined by measuring [3H]-thymidine incorporation with a beta counter (Wallac 1450 MicroBeta). For the ELISPOT assay, 96 well Multiscreen HTS plates (Millipore, Billerica, MA) were coated with capture mAbs directed at murine IFN-γ, IL-4 or IL-17A. Purified CD4+ T cells (105/well), mitomycin C-treated BMDCs (104 /well) and the indicated stimuli were incubated at 37°C for 42–45 h. Samples were run in duplicate except for one experiment that was run singly. Plates were then developed with BCIP (5-bromo-4-chloro-3-indolyl phosphate) / NBT solution and the number of spots enumerated using an Immunospot ELISPOT reader (Cellular Technology Ltd, Shaker Heights, OH).

Statistics

Data were analyzed and figures prepared using GraphPad Prism Software. For comparisons of three or more groups, the one-way ANOVA with the Tukey multiple comparison was performed. Experiments comparing two groups were analyzed using a two-tailed unpaired Student t-test with Bonferroni's correction applied for multiple comparisons. Significance was defined as p < 0.05.

Results

Role of Dectin-1 and complement in the phagocytosis of GPs in vitro

Here we confirmed our previous finding that uptake of unopsonized fluorescent-GPs by wild-type murine BMDCs is dependent on Dectin-1 and could be inhibited by low molecular weight Dectin-1 antagonist laminarin (21) (Fig 1A). However, particulate β-1,3-D-glucans are potent complement activators (10). Therefore, we studied uptake under conditions where an intact complement system was present, as would be expected to occur under typical in vivo conditions. After GPs were opsonized with fresh mouse serum from wild-type mice, uptake was slightly increased and was no longer inhibited by laminarin (Fig 1A). Destroying complement activity of mouse serum by heating to 56°C for 30 min restored the ability of laminarin to inhibit Dectin-1 mediated uptake of GPs (Fig 1A).

Figure 1
Effect of Dectin-1 and complement on phagocytosis of GPs by BMDCs in vitro

When the same experiments were performed with BMDCs from Dectin-1 deficient mice, a different pattern emerged. The critical role of Dectin-1 in facilitating phagocytosis of unopsonized GPs by BMDCs was recapitulated. Under conditions of no opsonization, almost no uptake of GPs by Dectin-1−/− BMDCs was observed (Fig 1B). However, when GPs were opsonized with fresh mouse serum, robust uptake was seen, even in the presence of laminarin. This increased phagocytosis was not seen if the serum was heat-inactivated, thereby inactivating complement. Finally, when GPs were opsonized with serum from C3−/− mice, the full effect of laminarin upon BMDC uptake of GPs was apparent (Fig 1C) because the effect of laminarin was not masked by the presence of active complement (C3). Under all opsonic and non-opsonic conditions, careful epifluorescent microscopy confirmed that the vast majority of cell-associated GPs were internalized by the BMDCs (data not shown). Taken together, these results suggest that both complement and Dectin-1 contribute to the uptake of GPs in vitro.

Involvement of complement receptor 3 (CR3) in the ability of serum to facilitate GP phagocytosis

Activation of complement by GPs results in deposition of iC3b on the surface of the particles (10). As CR3 (CD11b/CD18) serves as the major receptor for processed complement component iC3b (12, 13), we next examined the effect of anti-CR3 mAbs on BMDC phagocytosis of GPs. In preliminary studies, we had demonstrated strong expression of CR3 on BMDCs (data not shown). In the presence of fresh wild-type mouse serum, anti-CR3 mAbs had a modest, but significant, inhibitory effect on GP uptake (Fig 2 B). This effect was enhanced when β-glucan receptor binding sites were inhibited with laminarin. These results suggest that CR3 on BMDCs mediates uptake of serum-opsonized GPs. Although CR3 has a direct β-glucan binding site (13), the anti-CR3 mAbs had no effect on uptake of unopsonized GPs or GPs incubated with heat-inactivated mouse serum (Fig 2 A and C), suggesting uptake through CR3's direct β-glucan binding site is minimal.

Figure 2
Involvement of CR3 in the phagocytosis of GPs by bone marrow-derived dendritic cells (BMDCs) in vitro

Roles of Dectin-1 and C3 in mediating GPs uptake by peritoneal cells

In order to study the roles of Dectin-1 and C3 in vivo, we examined the phagocytosis of GPs by peritoneal monocytes/macrophages, as defined by positive staining for F4/80+, after intra-peritoneal inoculation. For these experiments, some mice also were injected with the soluble β-glucan receptor antagonist laminarin. It has been shown that laminarin does not activate the complement system (10). Dextran, a soluble α-glucan, served as a negative polysaccharide control. Neither dextran nor laminarin had an effect on F-GPs phagocytosis in wild-type mice comparing to those receiving F-GPs only (Fig 3). Compared with wild-type mice, no significant differences in the percentages of F4/80+ cells containing associated GPs could be found in Dectin-1 knockout mice, regardless of the presence of laminarin (Fig 3). However, significantly reduced GP uptake by peritoneal monocytes/macrophages was observed in C3−/− mice; this was reduced further by the addition of laminarin (Fig 3). These results suggest that while both Dectin-1 and complement receptors contribute to recognition of particulate β-glucans in vivo, complement plays a dominant role.

Figure 3
Effect of Dectin-1 and C3 on the phagocytosis of GPs by peritoneal monocytes/macrophages in vivo

Contributions of Dectin-1 and C3 to immune responses following GP-based vaccination

We have demonstrated that immunization of mice with antigen-loaded GPs elicits both strong humoral and Th1/Th17-biased CD4+ T cell responses (18). To assess the relative contributions of Dectin-1 and complement, anti-OVA Ab development, CD4+ T cell proliferation and T helper ELISPOT were compared in wild-type, Dectin-1−/− and C3−/− mice, each immunized with GP-OVA. IgG1 and IgG2c anti-OVA Abs were induced at similar titers in all three mouse strains (Fig 4A & B). CD4+ T cells from C3−/− mice proliferated slightly more than those from wild-type mice, both in response to OVA and to the mitogen, Con A (Fig 4C). Although no significant differences were seen in the number of OVA-specific IFN-γ or IL-4 producing CD4+ T cells among the three mouse strains, OVA specific IL-17A producing CD4+ T cells from C3 knockout mice were significant reduced compared with those from wild-type or Dectin-1−/− mice (Fig 4D).

Figure 4
Effects of Dectin-1 and C3 on the adaptive responses of mice immunized with GP-OVA

Discussion

The immunological consequences of ligation of β-glucans with Dectin-1 and other β-glucan receptors have received considerable study in the past decade (reviewed in (26)). However, β-glucans are also potent alternative complement pathway activators (911). Thus, in order to formulate an integrated model of how β-glucans interact with the immune system, the role of complement must be taken into account. Here we studied the relative contributions of Dectin-1 and complement to immune responses to GPs. As GPs do not contain mannans, lipids or proteins, their use allows the dissection of responses to particulate β-glucans without the confounding contributions of these other ligands. We found that complement facilitated the phagocytosis of GPs both in vitro and in vivo. More importantly, Dectin-1 was dispensable for Ab and CD4+ T cell responses to antigen-loaded particulate β-glucans in vivo. In contrast, while complement was redundant for some immune responses, optimal CD4+ Th17 responses required an intact complement system.

We previously demonstrated that Dectin-1 was indispensable for the phagocytosis of GPs by BMDCs in vitro (21). However, those studies used tissue culture media containing heat-inactivated fetal bovine serum and thus did not take into account that particulate β-1,3-D-glucans are potent complement activators (10). Indeed, when fresh serum was used to opsonize GPs, phagocytosis by BMDCs proceeded, even if Dectin-1 deficient BMDCs were used, or if β-glucan receptors were blocked with laminarin.

Opsonization of GPs with complement-sufficient serum results in dispersal on the GP surface of iC3b (10). While some DC populations do not express the iC3b receptor, CR3, BMDCs do and blocking CR3 with anti-CR3 mAbs inhibited the uptake of opsonized GPs. This effect was more profound when β-glucan receptors were blocked with laminarin. However, some phagocytosis was still observed that could have been mediated by the DC cell surface protein, CD11c/CD18, which also binds iC3b (27).

In some experimental systems, Dectin-1 is required for β-glucan-induced Th17 development in vitro (2830). In addition, recent in vivo studies show that Dectin-1 is essential for the adjuvant effect of the bacterial β-1,3-D-glucan, curdlan, and the anti-tumor activity of particulate β-glucans (30, 31). However, in our studies, wild-type and Dectin-1−/− mice immunized with GP-OVA developed similar OVA-specific Ab titers, CD4+ T cell proliferative responses and CD4+ T cell skewing. The reason for this discrepancy is speculative but may be explained by differences in how the antigens were delivered. In our system, OVA was encapsulated inside of GPs and thus the antigen and β-glucan were targeted directly to the same compartments within APCs. In contrast, in the aforementioned studies, the antigens and β-glucans were admixed and therefore would not necessarily traffic to the same intracellular compartment. Co-localization of antigen and PAMPs has been shown to increase the efficiency of the T cell response (32) and may thereby diminish the need for Dectin-1. In addition, in the absence of Dectin-1, complement receptors and other β-glucan receptors, such as the scavenger receptors SCARF1, CD36 and CD5 may compensate for the activities of Dectin-1 (3335). Indeed, β-glucan signaling through CD36 has been shown to induce cytokines (34).

Although the complement system was originally thought to contribute only to innate immunity against pathogens, more recent studies support the concept that complement activation can instruct B and T cell development (reviewed in (36, 37)). Complement activation by GPs results in the generation of the cleavage products, C3a and C5a (10). Interaction of these chemoattractants with their cognate receptors may influence Th17 development. In models of asthma and infection, mouse strains deficient in C3aR1 have impaired CD4+ Th17 cell responses whereas C5a receptor knockout mice mount enhanced IL-17A responses (3840). The importance of the C5a-C5aR pathway in Th17 cell development also has been demonstrated in an autoimmune arthritis model (41). C3 is central to all three complement activation pathways and C3 deficiency will generally result in the loss of complement function. Interestingly though, in the absence of C3, thrombin can substitute as a C5 convertase to generate C5a, albeit at reduced levels (42). Future studies will be needed to dissect the contributions of C3a and C5a to the Th17 responses observed following immunization with antigen-loaded GPs. Additionally, the relative contributions of the alternative and classical pathways of complement activation needs delineation. While GPs directly activate the alternative pathway (10), recent data demonstrating that mice have natural IgM Abs against β-glucans suggest that the classical complement pathway could also be activated by GPs (43).

How the immune system specifically responds to particulate β-glucans is difficult to reconcile with models that utilize live fungal challenges. In addition to β-glucans, fungi have multiple other PAMPs, such as mannans, that are innately recognized by the host immune system (2). In addition to serving as a vaccine platform, antigen-loaded GPs serve as a tool to study how β-glucan recognition contributes to immune responses to fungal antigens. Our data suggest a redundant role for Dectin-1 in the generation of systemic CD4+ T cell and Ab responses to antigens within particulate β-glucans. This redundancy appears to be explained by the ability of complement activation by β-glucans to license immune responses to associated antigens. However, it will be important to examine whether Dectin-1 is required for optimal mucosal immune responses, particularly given the association of mutations in Dectin-1 genes with mucosal candidiasis (7). In summary, our data suggest a dominant role for complement and a redundant role for Dectin-1 in both phagocytosis of GPs and CD4+ Th17-skewing following GP-based immunization.

Footnotes

1This work was supported by grants RO1AI025780 and R21AI093302 from the National Institutes of Health.

References

1. Latge JP. The cell wall: a carbohydrate armour for the fungal cell. Mol Microbiol. 2007;66:279–290. [PubMed]
2. Levitz SM. Innate recognition of fungal cell walls. PLoS Pathog. 2010;6:e1000758. [PMC free article] [PubMed]
3. Brown GD, Gordon S. Immune recognition. A new receptor for beta-glucans. Nature. 2001;413:36–37. [PubMed]
4. Drummond RA, Brown GD. The role of Dectin-1 in the host defence against fungal infections. Curr Opin Microbiol. 2011;14:392–399. [PubMed]
5. Taylor PR, Tsoni SV, Willment JA, Dennehy KM, Rosas M, Findon H, Haynes K, Steele C, Botto M, Gordon S, Brown GD. Dectin-1 is required for beta-glucan recognition and control of fungal infection. Nat Immunol. 2007;8:31–38. [PMC free article] [PubMed]
6. Saijo S, Fujikado N, Furuta T, Chung SH, Kotaki H, Seki K, Sudo K, Akira S, Adachi Y, Ohno N, Kinjo T, Nakamura K, Kawakami K, Iwakura Y. Dectin-1 is required for host defense against Pneumocystis carinii but not against Candida albicans. Nat Immunol. 2007;8:39–46. [PubMed]
7. Ferwerda B, Ferwerda G, Plantinga TS, Willment JA, van Spriel AB, Venselaar H, Elbers CC, Johnson MD, Cambi A, Huysamen C, Jacobs L, Jansen T, Verheijen K, Masthoff L, Morre SA, Vriend G, Williams DL, Perfect JR, Joosten LA, Wijmenga C, van der Meer JW, Adema GJ, Kullberg BJ, Brown GD, Netea MG. Human dectin-1 deficiency and mucocutaneous fungal infections. N Engl J Med. 2009;361:1760–1767. [PMC free article] [PubMed]
8. Rosentul DC, Plantinga TS, Oosting M, Scott WK, Velez Edwards DR, Smith PB, Alexander BD, Yang JC, Laird GM, Joosten LA, van der Meer JW, Perfect JR, Kullberg BJ, Netea MG, Johnson MD. Genetic variation in the dectin-1/CARD9 recognition pathway and susceptibility to candidemia. J Infect Dis. 2011;204:1138–1145. [PMC free article] [PubMed]
9. Pontieri GM, Plescia OJ, Nickerson WJ. Inactivation of Complement by Polysaccharides. J Bacteriol. 1963;86:1121–1122. [PMC free article] [PubMed]
10. Agarwal S, Specht CA, H H, Ostroff GR, Ram S, Rice PA, Levitz SM. Linkage specificity and role of properdin in activation of the alternative complement pathway by fungal glycans. MBio. 2011;2:00178–11. [PMC free article] [PubMed]
11. Pillemer L, Blum L, Lepow IH, Ross OA, Todd EW, Wardlaw AC. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. 1954;120:279–285. [PubMed]
12. Beller DI, Springer TA, Schreiber RD. Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor. J Exp Med. 1982;156:1000–1009. [PMC free article] [PubMed]
13. Ross GD, Cain JA, Lachmann PJ. Membrane complement receptor type three (CR3) has lectin-like properties analogous to bovine conglutinin as functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b. J Immunol. 1985;134:3307–3315. [PubMed]
14. Tsoni SV, Kerrigan AM, Marakalala MJ, Srinivasan N, Duffield M, Taylor PR, Botto M, Steele C, Brown GD. Complement C3 plays an essential role in the control of opportunistic fungal infections. Infect Immun. 2009;77:3679–3685. [PMC free article] [PubMed]
15. Allendorf DJ, Yan J, Ross GD, Hansen RD, Baran JT, Subbarao K, Wang L, Haribabu B. C5a-mediated leukotriene B4-amplified neutrophil chemotaxis is essential in tumor immunotherapy facilitated by anti-tumor monoclonal antibody and beta-glucan. J Immunol. 2005;174:7050–7056. [PubMed]
16. Hong F, Hansen RD, Yan J, Allendorf DJ, Baran JT, Ostroff GR, Ross GD. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 2003;63:9023–9031. [PubMed]
17. Yan J, Vetvicka V, Xia Y, Coxon A, Carroll MC, Mayadas TN, Ross GD. Beta-glucan, a “specific” biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18) J Immunol. 1999;163:3045–3052. [PubMed]
18. Huang H, Ostroff GR, Lee CK, Specht CA, Levitz SM. Robust stimulation of humoral and cellular immune responses following vaccination with antigen-loaded beta-glucan particles. MBio. 2010;1:00164–10. [PMC free article] [PubMed]
19. Young SH, Ostroff GR, Zeidler-Erdely PC, Roberts JR, Antonini JM, Castranova V. A comparison of the pulmonary inflammatory potential of different components of yeast cell wall. J Toxicol Environ Health A. 2007;70:1116–1124. [PubMed]
20. Hong F, Yan J, Baran JT, Allendorf DJ, Hansen RD, Ostroff GR, Xing PX, Cheung NK, Ross GD. Mechanism by which orally administered beta-1,3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol. 2004;173:797–806. [PubMed]
21. Huang H, Ostroff GR, Lee CK, Wang JP, Specht CA, Levitz SM. Distinct patterns of dendritic cell cytokine release stimulated by fungal beta-glucans and toll-like receptor agonists. Infect Immun. 2009;77:1774–1781. [PMC free article] [PubMed]
22. Soto ER, Ostroff GR. Characterization of multilayered nanoparticles encapsulated in yeast cell wall particles for DNA delivery. Bioconjug Chem. 2008;19:840–848. [PubMed]
23. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N, Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods. 1999;223:77–92. [PubMed]
24. Wozniak KL, Levitz SM. Cryptococcus neoformans enters the endolysosomal pathway of dendritic cells and is killed by lysosomal components. Infect Immun. 2008;76:4764–4771. [PMC free article] [PubMed]
25. Xia Y, Vetvicka V, Yan J, Hanikyrova M, Mayadas T, Ross GD. The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol. 1999;162:2281–2290. [PubMed]
26. Brown GD. Innate antifungal immunity: the key role of phagocytes. Annu Rev Immunol. 2011;29:1–21. [PMC free article] [PubMed]
27. Myones BL, Dalzell JG, Hogg N, Ross GD. Neutrophil and monocyte cell surface p150,95 has iC3b-receptor (CR4) activity resembling CR3. J Clin Invest. 1988;82:640–651. [PMC free article] [PubMed]
28. Osorio F, LeibundGut-Landmann S, Lochner M, Lahl K, Sparwasser T, Eberl G, Reis e Sousa C. DC activated via dectin-1 convert Treg into IL-17 producers. Eur J Immunol. 2008;38:3274–3281. [PMC free article] [PubMed]
29. Agrawal S, Gupta S, Agrawal A. Human dendritic cells activated via dectin-1 are efficient at priming Th17, cytotoxic CD8 T and B cell responses. PLoS One. 2010;5:e13418. [PMC free article] [PubMed]
30. LeibundGut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, Schweighoffer E, Tybulewicz V, Brown GD, Ruland J, Reis e Sousa C. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol. 2007;8:630–638. [PubMed]
31. Qi C, Cai Y, Gunn L, Ding C, Li B, Kloecker G, Qian K, Vasilakos J, Saijo S, Iwakura Y, Yannelli JR, Yan J. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived beta-glucans. Blood. 2011;117:6825–6836. [PubMed]
32. Blander JM, Medzhitov R. Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature. 2006;440:808–812. [PubMed]
33. Tsoni SV, Brown GD. beta-Glucans and dectin-1. Ann N Y Acad Sci. 2008;1143:45–60. [PubMed]
34. Means TK, Mylonakis E, Tampakakis E, Colvin RA, Seung E, Puckett L, Tai MF, Stewart CR, Pukkila-Worley R, Hickman SE, Moore KJ, Calderwood SB, Hacohen N, Luster AD, El Khoury J. Evolutionarily conserved recognition and innate immunity to fungal pathogens by the scavenger receptors SCARF1 and CD36. J Exp Med. 2009;206:637–653. [PMC free article] [PubMed]
35. Vera J, Fenutria R, Canadas O, Figueras M, Mota R, Sarrias MR, Williams DL, Casals C, Yelamos J, Lozano F. The CD5 ectodomain interacts with conserved fungal cell wall components and protects from zymosan-induced septic shock-like syndrome. Proc Natl Acad Sci U S A. 2009 [PubMed]
36. Heeger PS, Kemper C. Novel roles of complement in T effector cell regulation. Immunobiology. 2011 [PubMed]
37. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol. 2010;11:785–797. [PMC free article] [PubMed]
38. Bera MM, Lu B, Martin TR, Cui S, Rhein LM, Gerard C, Gerard NP. Th17 cytokines are critical for respiratory syncytial virus-associated airway hyperreponsiveness through regulation by complement C3a and tachykinins. J Immunol. 2011;187:4245–4255. [PMC free article] [PubMed]
39. Lajoie S, Lewkowich IP, Suzuki Y, Clark JR, Sproles AA, Dienger K, Budelsky AL, Wills-Karp M. Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat Immunol. 2010;11:928–935. [PMC free article] [PubMed]
40. Zhang X, Schmudde I, Laumonnier Y, Pandey MK, Clark JR, Konig P, Gerard NP, Gerard C, Wills-Karp M, Kohl J. A critical role for C5L2 in the pathogenesis of experimental allergic asthma. J Immunol. 2010;185:6741–6752. [PubMed]
41. Hashimoto M, Hirota K, Yoshitomi H, Maeda S, Teradaira S, Akizuki S, Prieto-Martin P, Nomura T, Sakaguchi N, Kohl J, Heyman B, Takahashi M, Fujita T, Mimori T, Sakaguchi S. Complement drives Th17 cell differentiation and triggers autoimmune arthritis. J Exp Med. 2010;207:1135–1143. [PMC free article] [PubMed]
42. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, Lambris JD, Warner RL, Flierl MA, Hoesel LM, Gebhard F, Younger JG, Drouin SM, Wetsel RA, Ward PA. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006;12:682–687. [PubMed]
43. Rapaka RR, Ricks DM, Alcorn JF, Chen K, Khader SA, Zheng M, Plevy S, Bengten E, Kolls JK. Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina. J Exp Med. 2010;207:2907–2919. [PMC free article] [PubMed]